NASDAQ NMS - GLOBAL MARKET · IPSC
-1.18% · -$0.0200 · Vol 457.0K
Market closed · last close 4:00 PM ET · price as of 16:01:46 ET
Century Therapeutics Inc

Century Therapeutics Inc

Biotechnology
$1.67
Card
Relationship Map

Follow $IPSC

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $IPSC by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
IPSC
Century Therapeutics Inc
Fri Sep 25 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

68/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: HIGH · 6 of 6 factors measured · Fri Sep 25 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is IPSC moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading IPSC catalysts
About Century Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2021
Employees
78
Country
US

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.70
Day high
$1.78
Day low
$1.63
Previous close
$1.69
52W high
$2.94
-43.20% from high
52W low
$0.4645
49% of range
Market cap
$302.4M
EPS
$-1.0600
Beta
1.17
Shares out
181.1M
Volume
457K
0.98× rel vol
Avg volume
464K
VWAP
$1.67
Price history computed in-house
1W
-10.22%
1M
-17.53%
3M
-30.71%
1Y
+228.03%
YTD
+67.87%
SMA 50 $2.02 · below
SMA 200 $2.04 · below
52W position 49%

IPSC overview

Loading financial statements
Loading IPSC Form 4 filings
Public disclosures

Congress activity in IPSC

No receipt-qualified Congressional disclosure is present for IPSC in the cached public ledger.

Federal contracts

IPSC contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IPSC in this window.
Lobbying spend

IPSC lobbying filings, year to date.

Registered lobbying filings matched to Century Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IPSC in this window.
Loading news for IPSC
Analyst ratings
Sovereign unlock shows live analyst consensus for IPSC.
Options
Sovereign unlock shows live options positioning for IPSC.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.